Search results
Results from the WOW.Com Content Network
Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [21] [22] The most common side effects are joint and muscle pain in the arms or legs. [23]
Denosumab is a monoclonal antibody [33] [34] which is administrated subcutaneously. It inhibits osteoclast differentiation and activation, reduces bone resorption, improves bone density and lessens skeletal-related events associated with metastasis.
Denosumab: SC: RANKL inhibitor. Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell.
Prolia, approved in 2010 to treat bone loss in postmenopausal women and later approved to treat men and women at high risk of fracture, brought in total third-quarter sales of $986 million.
Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. “The terms of the ...
However, there is no evidence of fracture rate reduction in patients taking a teriparatide and denosumab combination. The first such trial was published by Leder et al. in Lancet in 2013 with further data subsequently published in JCEM in a trial of post menopausal osteoporotic women demonstrating larger bone mineral density increases in the ...
The World Anti-Doping Agency on Monday offered an explanation for why top-ranked tennis player Jannik Sinner received a much shorter doping ban than the six-year suspension it handed to a Spanish ...
The general chemical structure of bisphosphonate. The R-groups determine the chemical properties of the drug, and distinguishes individual types of bisphosphonates. This chemical structure affords a high affinity for calcium hydroxyapatite, allowing for rapid and specific skeletal targeting.